These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 31315668)

  • 1. Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma.
    Gottlow M; Svensson DJ; Lipkovich I; Huhn M; Bowen K; Wessman P; Colice G
    BMC Pulm Med; 2019 Jul; 19(1):129. PubMed ID: 31315668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials.
    Panettieri RA; Sjöbring U; Péterffy A; Wessman P; Bowen K; Piper E; Colice G; Brightling CE
    Lancet Respir Med; 2018 Jul; 6(7):511-525. PubMed ID: 29792288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
    Brightling CE; Chanez P; Leigh R; O'Byrne PM; Korn S; She D; May RD; Streicher K; Ranade K; Piper E
    Lancet Respir Med; 2015 Sep; 3(9):692-701. PubMed ID: 26231288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program.
    Panettieri RA; Wang M; Braddock M; Bowen K; Colice G
    Immunotherapy; 2018 Mar; 10(6):473-490. PubMed ID: 29536781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma.
    Carlsson M; Braddock M; Li Y; Wang J; Xu W; White N; Megally A; Hunter G; Colice G
    Drug Saf; 2019 Jun; 42(6):769-784. PubMed ID: 30649752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
    Russell RJ; Chachi L; FitzGerald JM; Backer V; Olivenstein R; Titlestad IL; Ulrik CS; Harrison T; Singh D; Chaudhuri R; Leaker B; McGarvey L; Siddiqui S; Wang M; Braddock M; Nordenmark LH; Cohen D; Parikh H; Colice G; Brightling CE;
    Lancet Respir Med; 2018 Jul; 6(7):499-510. PubMed ID: 29793857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma.
    Bacharier LB; Pavord ID; Maspero JF; Jackson DJ; Fiocchi AG; Mao X; Jacob-Nara JA; Deniz Y; Laws E; Mannent LP; Amin N; Akinlade B; Staudinger HW; Lederer DJ; Hardin M
    J Allergy Clin Immunol; 2024 Jul; 154(1):101-110. PubMed ID: 38272375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis.
    Busse WW; Wenzel SE; Casale TB; FitzGerald JM; Rice MS; Daizadeh N; Deniz Y; Patel N; Harel S; Rowe PJ; Graham NMH; O'Riordan T; Pavord ID
    Lancet Respir Med; 2021 Oct; 9(10):1165-1173. PubMed ID: 34181876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
    Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
    Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.
    Hanania NA; Korenblat P; Chapman KR; Bateman ED; Kopecky P; Paggiaro P; Yokoyama A; Olsson J; Gray S; Holweg CT; Eisner M; Asare C; Fischer SK; Peng K; Putnam WS; Matthews JG
    Lancet Respir Med; 2016 Oct; 4(10):781-796. PubMed ID: 27616196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.
    Hanania NA; Wenzel S; Rosén K; Hsieh HJ; Mosesova S; Choy DF; Lal P; Arron JR; Harris JM; Busse W
    Am J Respir Crit Care Med; 2013 Apr; 187(8):804-11. PubMed ID: 23471469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
    Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
    Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma.
    Porsbjerg CM; Townend J; Bergeron C; Christoff GC; Katsoulotos GP; Larenas-Linnemann D; Tran TN; Al-Lehebi R; Bosnic-Anticevich SZ; Busby J; Hew M; Kostikas K; Papadopoulos NG; Pfeffer PE; Popov TA; Rhee CK; Sadatsafavi M; Tsai MJ; Ulrik CS; Al-Ahmad M; Altraja A; Beastall A; Bulathsinhala L; Carter V; Cosio BG; Fletton K; Hansen S; Heaney LG; Hubbard RB; Kuna P; Murray RB; Nagano T; Pini L; Cano Rosales DJ; Schleich F; Wechsler ME; Amaral R; Bourdin A; Brusselle GG; Chen W; Chung LP; Denton E; Fonseca JA; Hoyte F; Jackson DJ; Katial R; Kirenga BJ; Koh MS; Ławkiedraj A; Lehtimäki L; Liew MF; Mahboub B; Martin N; Menzies-Gow AN; Pang PH; Papaioannou AI; Patel PH; Perez-De-Llano L; Peters MJ; Ricciardi L; Rodríguez-Cáceres B; Solarte I; Tay TR; Torres-Duque CA; Wang E; Zappa M; Abisheganaden J; Assing KD; Costello RW; Gibson PG; Heffler E; Máspero J; Nicola S; Perng Steve DW; Puggioni F; Salvi S; Sheu CC; Sirena C; Taillé C; Tan TL; Bjermer L; Canonica GW; Iwanaga T; Jiménez-Maldonado L; Taube C; Brussino L; Price DB
    Front Immunol; 2024; 15():1361891. PubMed ID: 38711495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial.
    Heaney LG; Busby J; Hanratty CE; Djukanovic R; Woodcock A; Walker SM; Hardman TC; Arron JR; Choy DF; Bradding P; Brightling CE; Chaudhuri R; Cowan DC; Mansur AH; Fowler SJ; Niven RM; Howarth PH; Lordan JL; Menzies-Gow A; Harrison TW; Robinson DS; Holweg CTJ; Matthews JG; Pavord ID;
    Lancet Respir Med; 2021 Jan; 9(1):57-68. PubMed ID: 32916135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Safety and Efficacy of Anti-IL-13 Treatment with Tralokinumab (CAT-354) in Moderate to Severe Asthma: A Systematic Review and Meta-Analysis.
    Zhang Y; Cheng J; Li Y; He R; Pan P; Su X; Hu C
    J Allergy Clin Immunol Pract; 2019; 7(8):2661-2671.e3. PubMed ID: 31152798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma.
    Kraft M; Brusselle G; FitzGerald JM; Pavord ID; Keith M; Fagerås M; Garcia Gil E; Hirsch I; Goldman M; Colice G
    Eur Respir J; 2021 Dec; 58(6):. PubMed ID: 34112734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated fractional exhaled nitric oxide (FeNO) is a clinical indicator of uncontrolled asthma in children receiving inhaled corticosteroids.
    Yin SS; Liu H; Gao X
    Int J Clin Pharmacol Ther; 2017 Jan; 55(1):66-77. PubMed ID: 27443657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of Clinical Response to Dupilumab in Patients with Severe Asthma Using Fractional Exhaled Nitric Oxide Combined with Pulmonary Function Testing.
    Liu YL; Zhang Y
    Int Arch Allergy Immunol; 2024; 185(9):856-864. PubMed ID: 38688250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between total serum immunoglobulin E levels, fractional exhaled breath nitric oxide levels and absolute blood eosinophil counts in atopic and non-atopic asthma: a controlled comparative study.
    Shrestha SK; Drews A; Sharma L; Pant S; Shrestha S; Neopane A
    J Breath Res; 2018 Feb; 12(2):026009. PubMed ID: 29068321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disconnect of type 2 biomarkers in severe asthma; dominated by FeNO as a predictor of exacerbations and periostin as predictor of reduced lung function.
    Mansur AH; Srivastava S; Sahal A
    Respir Med; 2018 Oct; 143():31-38. PubMed ID: 30261989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.